Cantor Fitzgerald Suspends Neutral Rating on Apellis Pharmaceuticals

Benzinga Newsdesk www.benzinga.com Negative 85.7%

Neg 85.7% Neu 0% Pos 0%

Cantor Fitzgerald suspends Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS).

Comments

No comments yet. Be the first!